DB:5MPB

Stock Analysis Report

Executive Summary

Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom.


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Midatech Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5MPB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.1%

5MPB

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-84.6%

5MPB

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 5MPB underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 5MPB underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

5MPBIndustryMarket
7 Day9.1%11.2%7.3%
30 Day23.5%-5.3%-17.9%
90 Day-27.6%-21.9%-25.8%
1 Year-84.6%-84.6%-4.9%-5.1%-15.1%-17.7%
3 Year-99.2%-99.2%17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Midatech Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Midatech Pharma undervalued compared to its fair value and its price relative to the market?

0.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 5MPB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 5MPB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 5MPB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 5MPB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5MPB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5MPB is good value based on its PB Ratio (0.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Midatech Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Midatech Pharma performed over the past 5 years?

-4.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5MPB is currently unprofitable.

Growing Profit Margin: 5MPB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5MPB is unprofitable, and losses have increased over the past 5 years at a rate of -4% per year.

Accelerating Growth: Unable to compare 5MPB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5MPB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 5MPB has a negative Return on Equity (-37.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Midatech Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 5MPB's short term assets (£14.3M) exceed its short term liabilities (£3.4M).

Long Term Liabilities: 5MPB's short term assets (£14.3M) exceed its long term liabilities (£383.0K).


Debt to Equity History and Analysis

Debt Level: 5MPB's debt to equity ratio (3.4%) is considered satisfactory.

Reducing Debt: 5MPB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: 5MPB has a low level of unsold assets or inventory.

Debt Coverage by Assets: 5MPB's debt is covered by short term assets (assets are 17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 5MPB has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 5MPB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Midatech Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5MPB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5MPB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5MPB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5MPB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5MPB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Craig Cook (52yo)

1.75s

Tenure

UK£158,772

Compensation

Dr. Craig Richard Cook, MBBCH, BSc (Hons), DA, MD, MBA has been Chief Executive Officer and Director of Midatech Pharma Plc since June 1, 2018 and served as its Chief Operating Officer since January 1, 201 ...


CEO Compensation Analysis

Compensation vs Market: Craig's total compensation ($USD197.08K) is below average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Craig Cook
CEO & Director1.75yrsUK£158.77k0.027% £1.6k
Stephen Stamp
CFO & Director0.50yrno data0.21% £13.2k
Tim Sparey
Chief Business Officerno datano datano data
Justin Barry
Head of Manufacturingno datano datano data
Steve Damment
Head of Research & Development2yrsno datano data
David Benharris
President of Midatech Pharma US Inc4.17yrsno datano data

1.9yrs

Average Tenure

54yo

Average Age

Experienced Management: 5MPB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Craig Cook
CEO & Director1.75yrsUK£158.77k0.027% £1.6k
Stephen Stamp
CFO & Director0.50yrno data0.21% £13.2k
Simon Turton
Senior Independent Non-Executive Director5.25yrsUK£30.40k0.24% £14.6k
Rolf Stahel
Non-Executive Chairman6yrsUK£95.00k0.13% £7.9k
Daniel McCurdy
Member of Scientific Advisory Boardno datano datano data
Sijmen de Vries
Non-Executive Director15.42yrsUK£30.40k0.093% £5.7k
Francesco Stellaci
Chairman of Scientific Advisory Boardno datano datano data
David Male
Member of Scientific Advisory Boardno datano datano data
Lorraine O'Driscoll
Member of Scientific Advisory Boardno datano datano data
Soledad Penades
Member of Scientific Advisory Boardno datano datano data

5.3yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 5MPB's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 215.5%.


Top Shareholders

Company Information

Midatech Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Midatech Pharma plc
  • Ticker: 5MPB
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£5.521m
  • Listing Market Cap: UK£6.181m
  • Shares outstanding: 23.49m
  • Website: https://www.midatechpharma.com

Number of Employees


Location

  • Midatech Pharma plc
  • Oddfellows House
  • 19 Newport Road
  • Cardiff
  • South Glamorgan
  • CF24 0AA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTPHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2014
5MPBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2014
MTPNasdaqCM (Nasdaq Capital Market)SPON ADS EACH REP 20 ORD SHS(R/S)USUSDDec 2015
5MPABST (Boerse-Stuttgart)SPON ADS EACH REP 20 ORD SHS(R/S)DEEURDec 2015
5MPDDB (Deutsche Boerse AG)SPON ADS EACH REP 20 ORD SHS(R/S)DEEURDec 2015

Biography

Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, a nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, which is designed for targeted delivery to enable improved delivery of therapeutics to tumor cells and the immune system. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 00:10
End of Day Share Price2020/03/27 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.